Boosting Confidence in Early-Stage Drug Candidates Through Orthogonal Readouts & SAR Analysis
Time: 4:15 pm
day: Day One
Details:
- Integrating multiple assay platforms to validate hit specificity for targeting DHX9 and KIF18A
- Adopting a SAR analysis approach for fine-turning compound structure and improving bioactivity
- Combining assay expertise with deep cancer biology to succeed in hit binding and minimize off-target effects
